When does rexulti go generic?

Short answer:
As of now, Rexulti (brexpiprazole) is still protected by patents, so no U.S. generic version has been approved. The earliest that a generic could realistically appear in the United States would be around 2029–2030, once the last of the key patents expires and a qualified manufacturer files a New Drug Application (NDA) that is approved by the FDA.

Why 2029–2030?

What happens in other markets?

• Canada & EU: Patents in those jurisdictions also expire around 2029–2030, so generic approval timelines are similar.
• Australia & Japan: Patents are typically aligned with U.S. dates, so generics there are also not expected until 2029–2031.

How to keep up-to-date

1. FDA’s “Drugs@FDA” database – Search for “brexpiprazole” and look for any “generic” status.
2. Patent status tools – Sites like USPTO, European Patent Office, or the Canadian Intellectual Property Office list expiry dates.
3. News releases – Eli Lilly or generic manufacturers occasionally announce filing intentions or approval dates.

Bottom line

• No generic Rexulti in the U.S. yet.
• Earliest realistic launch: Late 2029–2030.
• Check FDA and patent offices if you need the exact filing date once the generic manufacturer submits their NDA.

Feel free to let me know if you’d like help tracking a specific generic applicant or if you have questions about how generic pricing works once it does become available!